Hims & Hers prices $350 million convertible notes offering – Image for illustrative purposes only (Image credits: Unsplash)
Hims & Hers Health has priced an upsized offering of zero-coupon convertible senior notes due in 2032. The telehealth company lifted the size from an initial $300 million target to $350 million after strong investor interest. Proceeds will help fund international growth and further investment in its AI platform while preserving balance-sheet flexibility.
Financing Details Take Shape
The notes carry no regular interest payments and will mature on June 1, 2032. Investors receive an initial conversion rate of 33.8590 shares of Class A common stock for every $1,000 in principal. Hims & Hers also granted buyers an option to purchase up to an additional $52.5 million in notes within 13 days of the first settlement.
Net proceeds are expected to reach roughly $338.5 million, or about $389.5 million if the full option is exercised. The company plans to allocate approximately $32 million of those funds to capped-call transactions that limit potential dilution from conversions. Settlement is scheduled for May 21, 2026, subject to standard closing conditions.
Strategic Uses Drive the Decision
Management intends to deploy the capital toward international expansion and accelerated development of its AI-driven platform. A key element of the overseas push is the proposed acquisition of Eucalyptus, an Australian telehealth business expected to close in mid-2026. The financing gives Hims & Hers additional runway without immediate pressure on cash flow or existing credit lines.
Market reaction was mixed. Shares of Hims & Hers fell about 7 percent on the day the offering was first announced, a common response when companies issue convertible securities that could eventually dilute existing holders. Still, the upsizing signals robust demand from qualified institutional buyers under Rule 144A.
Context Within Broader Growth Trajectory
Hims & Hers has expanded rapidly in recent years by offering personalized health and wellness products through a direct-to-consumer model. The company now serves millions of subscribers across multiple therapeutic areas, including weight management and mental health. Adding international markets and deeper AI capabilities represents the next phase of that expansion.
Zero-coupon convertibles allow the firm to raise capital at a low explicit cost while giving investors equity upside if the stock performs well. This structure aligns with the company’s long-term growth outlook and its desire to keep near-term interest expenses minimal.
What Matters Now
The $350 million raise positions Hims & Hers to execute on two high-priority initiatives at once: scaling outside the United States and embedding more artificial intelligence across its platform. Investors will watch closely for updates on the Eucalyptus deal and any early returns from the AI investments.
